About this trial
Ascending aortic aneurysms (AAAs) are serious conditions that can lead to aortic dissections or ruptures, carrying a high risk of mortality. Their pathophysiology is based on complex mechanisms involving inflammatory and metabolic processes, as well as alterations in mitochondrial function. The presence of a bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV) significantly influences the progression and severity of aneurysms. Bicuspid aortic valve (BAV) patients often develop aortic aneurysms earlier, as early as age 40-50, whereas tricuspid aortic valve (TAV) patients generally present with a degenerative condition that appears later (after age 50). The objective of this study is to compare the inflammatory, metabolic, and transcriptomic signatures of myeloid cells and total aortic tissue between BAV and TAV patients. These analyses will help identify specific molecular mechanisms, potential biomarkers, and therapeutic targets. To ensure pathophysiological homogeneity, patients with aneurysms of genetic origin (Marfan syndrome, Loeys-Dietz syndrome, Ehlers-Danlos syndrome, etc.) will be excluded.
Eligibility criteria
Qualifiers
Individuals who have given their consent
Patients with an ascending aortic aneurysm for which surgical replacement is indicated
Age > 18 years
Scheduled surgery
Disqualifiers
A person subject to a legal protective measure (guardianship, conservatorship)
A person subject to a judicial safeguard measure - A pregnant woman, a woman in labor, or a breastfeeding woman
Adults who are legally incapacitated or unable to give consent
Emergency surgical procedures
Trial design
Treatments tested in this trial
- Additional blood samples
- Collection of discarded ascending aortic tissue